Australien - engelska - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Israel - engelska - Ministry of Health

perrigo israel agencies ltd - desonide - cream - desonide 0.1 % - desonide - desonide - treatment of dermatoses which require treatment with topical corticosteroids e.g. psoriasis, lichenipication, atopic dermatitis, contact dermatitis

Israel - engelska - Ministry of Health

perrigo israel agencies ltd - vinflunine ditartrate - concentrate for solution for infusion - vinflunine ditartrate 25 mg/ml - vinflunine - vinflunine - javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinium-containing regimen. efficacy and safety of vinflunine have not been studied in patients with performance status ≥2.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - excipient ingredients: - 1. cleanse, 2. soothe, 3. restore, 4. protect

Irland - engelska - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - chlorhexidine gluconate tetracaine hydrochloride - oromucosal spray, soln

Irland - engelska - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - mequitazine - tablets - 5 milligram

Irland - engelska - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - theophylline - 100 milligram

Irland - engelska - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - theophylline - 300 milligram